ARCHIVES

Pfizer’s Inlyta Gives FDA a Teaching Moment: Not All PFS Advantages Are Created Equal

This article is from The Cancer Letter archive.

Vol. 37 No. 46 | December 16, 2011

Download PDF Visit The Full Archive

Related Articles

Executive Summary of Centers, SPOREs Report

February 28, 2003

Hyperthermia Offers Prospects For Major Treatment Advance, Investigators Says

March 11, 1977

Radium 223 Dichloride Reduces Death Risk By 30 Percent in Castration-Resistant Disease

August 30, 2013

Impeding Reagan Budget Cuts Feared By Cancer Program Advocates; DeVita Asks Parity With NIH

February 13, 1981

Perifosine Fails Primary Endpoint, Zentaris CEO Explores Options

April 27, 2012

Clanton Resigns From NCI.

January 12, 2007